The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period.

A handful of ASX health stocks have seen their prices skyrocket during the past fortnight.

Onychomycosis (fungal infection in the nails) focused company Hexima (ASX:HXL) was one of the best performers over the fortnight, rocketing by almost 70%.

Investors have been buying HXL shares after it announced the completion of patients enrolment for its Phase IIb clinical trial evaluating pezadeftide (HXP124) as a potential new topical treatment for onychomycosis. The trial will be conducted at 15 sites in Australia and New Zealand, starting in Q2 of 2022.

Hexima is well-funded, having just raised $5.5m in an IPO and floated its shares on the ASX in December.

Bionomics (ASX:BNO) rose 33% this week, after announcing a plan to list American Depositary Receipts (ADRs) on the Nasdaq through an IPO.

The company is currently trying to develop a pipeline of drug candidates for patients affected by central nervous system (CNS) disorders. Bionomics believes that a listing in the US would provide it with the necessary access to capital to progress these studies.

Atomo Diagnostics (ASX:AT1) rose by 30% in the past two weeks after reporting a full year revenue of $6.7m, up 25% on previous corresponding period (pcp).

The company is about to launch the CareStart COVID-19 IgM/IgG antibody test, which is integrated with the Atomo Galileo device, in the US. This was made possible following an Emergency Use Authorisation (EUA) received from the FDA during the quarter.

 

Here’s a table showing how ASX-listed healthcare stocks have been performing.

Code Company Price %Mth %Wk MktCap
HXL Hexima 0 88 46 $ 30,694,964.30
TD1 Tali Digital Limited 0 47 18 $ 39,140,043.14
RNO Rhinomed Ltd 0 40 11 $ 53,299,917.72
S66 Star Combo 0 37 23 $ 47,149,364.15
AHC Austco Healthcare 0 30 7 $ 42,628,342.65
PIQ Proteomics Int Lab 1 27 -4 $ 119,991,697.50
ALT Analytica Limited 0 25 0 $ 11,534,502.82
LBT LBT Innovations 0 22 -13 $ 30,357,092.22
IDT IDT Australia Ltd 0 19 0 $ 95,944,068.00
AT1 Atomo Diagnostics 0 18 18 $ 96,042,229.20
DXB Dimerix Ltd 0 18 -2 $ 45,539,838.31
4DX 4Dmedical Limited 1 17 3 $ 310,829,262.00
CGS Cogstate Ltd 2 15 -7 $ 278,710,979.53
MDR Medadvisor Limited 0 15 10 $ 130,197,141.21
EPN Epsilon Healthcare 0 15 11 $ 30,833,111.84
HCT Holista CollTech Ltd 0 14 5 $ 18,173,039.74
OVN Oventus Medical Ltd 0 13 0 $ 25,381,286.18
AMT Allegra Orthopaedics 0 13 13 $ 22,981,024.66
MDC Medlab Clinical Ltd 0 12 0 $ 65,013,377.49
BXN Bioxyne Ltd 0 12 0 $ 17,924,071.14
CTE Cryosite Limited 0 12 4 $ 20,383,909.91
JHC Japara Healthcare Lt 1 11 0 $ 368,801,312.64
NC6 Nanollose Limited 0 9 11 $ 14,125,204.96
RAP Resapp Health Ltd 0 9 17 $ 34,367,883.08
PXS Pharmaxis Ltd 0 8 1 $ 44,839,492.24
MVF Monash IVF Group Ltd 1 6 3 $ 348,723,181.80
GSS Genetic Signatures 1 5 -8 $ 182,206,738.65
CMP Compumedics Limited 0 5 9 $ 70,865,179.20
RHY Rhythm Biosciences 1 5 -3 $ 194,083,978.56
1ST 1St Group Ltd 0 5 -4 $ 8,492,338.06
ILA Island Pharma 0 4 -5 $ 12,882,949.80
EYE Nova EYE Medical Ltd 0 3 2 $ 45,979,564.16
BNO Bionomics Limited 0 3 33 $ 196,481,365.08
PBP Probiotec Limited 2 2 3 $ 167,127,054.78
CBL Control Bionics 1 1 9 $ 32,893,377.54
AVE Avecho Biotech Ltd 0 0 6 $ 33,050,097.47
LDX Lumos Diagnostics 1 0 5 $ 190,693,564.51
EXL Elixinol Wellness 0 0 4 $ 39,382,894.25
MXC Mgc Pharmaceuticals 0 0 3 $ 93,390,041.96
PYC PYC Therapeutics 0 0 0 $ 477,138,915.45
NTI Neurotech Intl 0 0 0 $ 36,931,413.68
IMC Immuron Limited 0 0 0 $ 36,359,455.36
ICS ICSGlobal Limited 1 0 0 $ 6,054,604.94
FFC Farmaforce Ltd 0 0 0 $ 8,755,625.66
AHK Ark Mines Limited 0 0 0 $ 1,778,919.95
OPT Opthea Limited 1 0 -2 $ 449,284,532.48
VBS Vectus Biosystems 1 -1 9 $ 40,835,458.26
RGS Regeneus Ltd 0 -1 1 $ 22,765,377.23
ALC Alcidion Group Ltd 0 -1 -9 $ 387,785,549.24
ONT 1300 Smiles Limited 7 -1 0 $ 165,748,688.00
NXS Next Science Limited 2 -2 -6 $ 300,920,341.68
SDI SDI Limited 1 -2 -1 $ 105,790,321.70
ARX Aroa Biosurgery 1 -2 -6 $ 344,732,147.10
IHL Incannex Healthcare 0 -2 -2 $ 256,476,078.48
PAA Pharmaust Limited 0 -2 -11 $ 29,139,152.64
BWX BWX Limited 5 -3 -3 $ 696,644,614.32
CAJ Capitol Health 0 -3 0 $ 375,255,591.88
NEU Neuren Pharmaceut. 2 -3 0 $ 183,372,972.80
NSB Neuroscientific 0 -3 -5 $ 45,193,567.55
RCE Recce Pharmaceutical 1 -4 -9 $ 163,351,176.18
SOM SomnoMed Limited 2 -4 -3 $ 192,415,407.38
M7T Mach7 Tech Limited 1 -4 2 $ 241,227,670.32
MEM Memphasys Ltd 0 -4 2 $ 49,450,302.20
OIL Optiscan Imaging 0 -4 13 $ 132,582,029.43
ZNO Zoono Group Ltd 1 -4 -18 $ 107,242,009.55
EZZ EZZ Life Science 0 -4 -4 $ 5,100,000.00
ANP Antisense Therapeut. 0 -5 11 $ 123,512,413.75
PCK Painchek Ltd 0 -5 9 $ 63,101,068.74
BIT Biotron Limited 0 -5 0 $ 41,414,030.07
APH AP Hemp Ltd 0 -5 -3 $ 28,271,749.95
VLS Vita Life Sciences.. 1 -5 -1 $ 56,075,031.78
CYC Cyclopharm Limited 2 -6 -4 $ 152,667,835.61
MEB Medibio Limited 0 -6 0 $ 13,462,961.24
SCU Stemcell United Ltd 0 -6 -16 $ 17,736,451.19
PAL Palla Pharma Ltd 0 -6 0 $ 59,907,870.31
IVX Invion Ltd 0 -7 0 $ 77,553,592.13
OSP Osprey Med Inc 0 -7 -13 $ 41,052,484.45
AC8 Auscann Grp Hlgs Ltd 0 -7 -2 $ 46,257,446.55
CHM Chimeric Therapeutic 0 -7 8 $ 63,970,827.38
VHT Volpara Health Tech 1 -7 0 $ 281,472,890.72
PSQ Pacific Smiles Grp 3 -7 5 $ 406,933,941.90
TRU Truscreen 0 -7 10 $ 23,223,440.19
PAR Paradigm Bio. 2 -7 -4 $ 447,641,384.13
MX1 Micro-X Limited 0 -7 2 $ 147,104,556.80
CYP Cynata Therapeutics 0 -7 -3 $ 70,921,914.03
KZA Kazia Therapeutics 1 -8 -5 $ 164,364,739.16
CDX Cardiex Limited 0 -8 3 $ 67,600,785.32
RAC Race Oncology Ltd 3 -8 -7 $ 485,186,832.48
GLH Global Health Ltd 0 -9 -3 $ 28,001,023.88
MVP Medical Developments 4 -9 7 $ 299,311,622.40
TLX Telix Pharmaceutical 5 -10 0 $ 1,534,847,573.60
OCC Orthocell Limited 1 -10 2 $ 104,821,283.05
IMM Immutep Ltd 0 -10 3 $ 404,188,330.48
MMJ MMJ Group Hlds Ltd 0 -10 -5 $ 18,626,272.79
ZLD Zelira Therapeutics 0 -10 -6 $ 52,374,210.50
BPH BPH Energy Ltd 0 -10 0 $ 47,209,276.62
RSH Respiri Limited 0 -11 5 $ 45,538,969.77
LSH Lifespot Health Ltd 0 -11 -2 $ 16,509,761.79
SHG Singular Health 0 -11 0 $ 17,790,707.55
GTG Genetic Technologies 0 -11 0 $ 73,808,721.14
JTL Jayex Technology Ltd 0 -11 -11 $ 5,290,890.70
ADR Adherium Ltd 0 -11 -11 $ 34,065,375.36
PGC Paragon Care Limited 0 -12 0 $ 89,539,602.38
IPD Impedimed Limited 0 -13 0 $ 146,411,656.90
DVL Dorsavi Ltd 0 -13 0 $ 9,124,246.87
DOC Doctor Care Anywhere 1 -13 -11 $ 145,155,178.44
ACR Acrux Limited 0 -14 -7 $ 35,413,174.25
AGH Althea Group 0 -14 -6 $ 80,023,929.70
CPH Creso Pharma Ltd 0 -15 0 $ 131,622,038.02
ATH Alterity Therap Ltd 0 -15 3 $ 79,426,861.07
PNV Polynovo Limited 2 -16 1 $ 1,514,578,620.76
NYR Nyrada Inc. 0 -16 -12 $ 36,870,854.10
UBI Universal Biosensors 1 -16 5 $ 142,142,812.80
ONE Oneview Healthcare 0 -17 -7 $ 173,306,101.20
NOX Noxopharm Limited 1 -17 -3 $ 167,168,601.66
PTX Prescient Ltd 0 -17 6 $ 112,451,424.40
CDY Cellmid Limited 0 -17 -9 $ 9,371,528.00
OSX Osteopore Limited 0 -18 0 $ 30,044,553.00
BOT Botanix Pharma Ltd 0 -18 -3 $ 72,012,513.48
IMU Imugene Limited 0 -18 -10 $ 1,500,907,573.20
ATX Amplia Therapeutics 0 -20 -14 $ 24,340,161.30
ADO Anteotech Ltd 0 -21 -9 $ 403,921,076.78
OSL Oncosil Medical 0 -22 6 $ 41,461,851.29
VTI Vision Tech, Inc 1 -22 -9 $ 26,944,470.00
LCT Living Cell Tech. 0 -24 -7 $ 7,428,732.75
PAB Patrys Limited 0 -24 -19 $ 72,783,876.20
ICR Intelicare Holdings 0 -24 -15 $ 6,807,841.50
RHT Resonance Health 0 -25 -10 $ 64,519,277.34
IBX Imagion Biosys Ltd 0 -26 -10 $ 76,114,539.82
SUD Suda Pharmaceuticals 0 -28 -4 $ 22,598,539.34
BD1 Bard1 Life Sciences 1 -29 -13 $ 119,795,070.23
ACW Actinogen Medical 0 -31 -18 $ 154,431,944.87
CAN Cann Group Ltd 0 -31 -12 $ 88,518,610.85
1AD Adalta Limited 0 -42 -10 $ 20,349,904.97
BDX Bcaldiagnostics 0.16 -20 $ 23,017,148.35

 

Worst performing health stocks in the past two weeks

Patrys (ASX:PAB)

PAB shares dropped 15% this week after announcing delays in procuring certain key components required for its PAT-DX1 clinical trial program. Patrys’ commercial contract manufacturer said the delays are entirely due to the impact of the COVID-19 pandemic on the production and supply chains, and are outside if its control.

The anticipated delay means the start of the GMP toxicology studies for PAT-DX1 has been rescheduled to Q1 CY 22.

BARD1 Life Sciences (ASX:BD1)

BD1 shares fell 24% over the past two weeks since announcing a $15m capital raising to accelerate its cancer diagnostic program.The company is collaborating with researchers at the University of Queensland (UQ) who are using the EXO-NET® product to develop a novel test for ovarian cancer based on exosomes isolated from the blood of cancer patients.

 

Notable health stocks announcements you might have missed

Chimeric Therapeutics (ASX:CHM)

The company obtaining the exclusive licence to a novel CAR-T for solid tumours from the University of Pennsylvania, which will bring its novel CDH17 CAR-T cell therapy to more patients. The novel therapy targets gastrointestinal tumors including colorectal cancer, pancreatic cancer and gastric cancer.

4D Medical (ASX:4DX)

The respiratory device specialist said it will ramp up commercialisation activities following the rapidly growing vaccination uptake in the US. This, 4DX says, will allow for greater access to key decision makers at hospitals and medical institutions, where it plans to commence several clinical trials for its XV Lung Ventilation Analysis Software (XV LVAS).

Hydrix (ASX:HYD)

The company said that Angel Medical Systems had completed its first commercial implantation in the US of the company’s Guardian device – a cardiac detection monitor and patient warning system.

The implant marks the first use of the Guardian following its recent FDA approval, and cardiac electrophysiologist and cardiologist Dr Andrew Kaplan – who performed the procedure – said it marks a “pivotal advancement in cardiac care”.